178 related articles for article (PubMed ID: 25888978)
21. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
Schilder RJ; Blessing JA; Shahin MS; Miller DS; Tewari KS; Muller CY; Warshal DP; McMeekin S; Rotmensch J
Int J Gynecol Cancer; 2010 Oct; 20(7):1137-41. PubMed ID: 21495215
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
[TBL] [Abstract][Full Text] [Related]
24. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
25. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Garcia AA; Blessing JA; Nolte S; Mannel RS;
Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
27. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
Moore DH; Blessing JA; Dunton C; Buller RE; Reid GC
Gynecol Oncol; 1999 Dec; 75(3):473-5. PubMed ID: 10600310
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study.
Covens A; Brunetto VL; Markman M; Orr JW; Lentz SS; Benda J;
Gynecol Oncol; 2003 Jun; 89(3):470-4. PubMed ID: 12798713
[TBL] [Abstract][Full Text] [Related]
29. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Westin SN; Sill MW; Coleman RL; Waggoner S; Moore KN; Mathews CA; Martin LP; Modesitt SC; Lee S; Ju Z; Mills GB; Schilder RJ; Fracasso PM; Birrer MJ; Aghajanian C
Gynecol Oncol; 2019 Dec; 155(3):420-428. PubMed ID: 31623857
[TBL] [Abstract][Full Text] [Related]
30. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
[TBL] [Abstract][Full Text] [Related]
32. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Lentz SS; Brady MF; Major FJ; Reid GC; Soper JT
J Clin Oncol; 1996 Feb; 14(2):357-61. PubMed ID: 8636744
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; Waggoner SE
Gynecol Oncol; 2002 Dec; 87(3):247-51. PubMed ID: 12468321
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.
Dizon DS; Blessing JA; McMeekin DS; Sharma SK; Disilvestro P; Alvarez RD
J Clin Oncol; 2009 Jul; 27(19):3104-8. PubMed ID: 19451430
[TBL] [Abstract][Full Text] [Related]
36. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Santin AD; Filiaci V; Bellone S; Ratner ES; Mathews CA; Cantuaria G; Gunderson CC; Rutledge T; Buttin BM; Lankes HA; Frumovitz M; Khleif SN; Huh WK; Birrer MJ
Gynecol Oncol Rep; 2020 Feb; 31():100532. PubMed ID: 31934607
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
[TBL] [Abstract][Full Text] [Related]
38. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Asbury RF; Brunetto VL; Lee RB; Reid G; Rocereto TF;
Am J Clin Oncol; 2002 Dec; 25(6):557-60. PubMed ID: 12477997
[TBL] [Abstract][Full Text] [Related]
39. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Leslie KK; Sill MW; Fischer E; Darcy KM; Mannel RS; Tewari KS; Hanjani P; Wilken JA; Baron AT; Godwin AK; Schilder RJ; Singh M; Maihle NJ
Gynecol Oncol; 2013 Jun; 129(3):486-94. PubMed ID: 23438670
[TBL] [Abstract][Full Text] [Related]
40. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]